Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy;La transcriptómica ilustra nuevas vías letales en la nefropatía diabética

Nefrologia

Volumn 29, Issue 1, 2009, Pages 13-19

  Benito Martin A ^a   Ucero, A C ^a   Santamaria B ^a   Lorz, C ^d   Kretzler, M ^e   Rastaldi, M P ^f   Sanchez Nino M D ^a   Sanz, A ^a   Izquierdo, M C ^a   Ruiz Ortega, M ^a,b   Egido, J ^a,b   Ortiz, A ^a,b,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Section of Nephrology   (Spain)

^d CIEMAT   (Spain)

^e UNIVERSITY OF MICHIGAN   (United States)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Apoptosis; CD74; Diabetes; Kidney; MIF; TRAIL

Indexed keywords

TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

DIABETIC NEPHROPATHY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; REVIEW;

DIABETIC NEPHROPATHIES; HUMANS; HYPERGLYCEMIA; INFLAMMATION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC;

EID: 67650753191     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kumar D, Robertson S, Burns KD. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 2004;259:67-70.
2. Sanz AB, Santamaría B, Ruiz Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008;19:1634-42.
3. Ruiz Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995;48:1778-91.
4. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008;19:771-9.
5. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, el at. on behalf of the PREDICTIONS Network. Urinary Proteomics in Diabetes and CKD. J Am Soc Nephrol 2008;19:1283-90.
6. Lorz C, Benito-Martín A, Boucherot A, Ucero AC, Rastaldi MP, Henger A, el at. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008;19:904-14.
7. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, el at. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006;11:2993-3003.
8. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med 1997;45:50-6.
9. Kelly DJ, Stein-Oakley A, Zhang Y, Wassef L, Maguire J, Koji T, et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with reninangiotensin blockade. Nephrology (Carlton) 2004;9:7-13.
10. González-Cuadrado S, Lorz C, García del Moral R, O'Valle F, Alonso C, Ramiro F, et al. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. Kidney Int 1997;51:1739-46.
11. Justo P, Sanz AB, Sánchez-Niño MD, Winkles JA, Lorz C, Egido J, el at. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006;70:1750-8.
12. Sanz AB, Justo P, Sánchez-Niño MD, Blanco-Colio LM, Winkles JA, Kreztler M, el at. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation. J Am Soc Nephrol 2008;19:695-703.
13. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. Nephrol Dial Transplant 1999;14:1831-4.
14. Lorz C, Ortiz A, Justo P, González-Cuadrado S, Duque N, Gómez-Guerrero C, el at. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000;11:1266-77.
15. Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006;17:441-50.
16. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
17. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, el at. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
18. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997;416:329-34.
19. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, el at. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7:831-6.
20. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47.
21. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008;263:14-25.
22. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 12004;13:58-64.
23. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, Grattan M, et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 2003;52:1967-75.
24. Lorz C, Benito A, Ucero AC, Santamaría B, Ortiz A. TRAIL and kidney disease. Front Biosci 2008 (in press).
25. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
26. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
27. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004;104:2044-50.
28. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-9.
29. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006;154:75-81.
30. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, el at. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
31. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, el at. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821-31.
32. Sánchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009 (in press).
33. Mensah-Brown EP, Obineche EN, Galadari S, Chandranath E, Shahin A, Ahmed I, el at. Streptozotocin-induced diabetic nephropathy in rats: The role of inflammatory cytokines. Cytokine 2005;31:180-90.
34. Baumgartner-Parzer SM, Wagner L, Pettermann M, Grillari J, Gessl A, Waldhausl W. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 1995;44:1323-7.
35. Moley KH, Chi MM, Knudson CM, Korsmeyer SJ, Mueckler MM. Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways. Nat Med 1998;4:1421-4.
36. Ortiz A, Lorz C, Catalán MP, Danoff TM, Yamasaki Y, Egido J, el at. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 2000;57:969-81.
37. Justo P, Sanz A, Lorz C, Egido J, Ortiz A. Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. Kidney Int 2003;64:52-6.
38. Justo J, Sanz AB, Lorz C, Egido J, Ortiz A. Lethal activity of FADD death domain in renal tubular epithelial cells. Kidney Int 2006;69:2205-11.
39. Koenig-Hoffmann K, Bonin-Debs AL, Boche I, Gawin B, Gnirke A, Hergersberg C, et al. High throughput functional genomics: identification of novel genes with tumor suppressor phenotypes. Int J Cancer 2005;113:434-9.
40. Song CJ, Liu XS, Zhu Y, Chen LH, Jia W, Li YN, et al. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation. Transplant Proc 2004;36:1340-3.